Skip to menu Skip to content Skip to footer

2022

Conference Publication

Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

Eifert, Theresa, Schnoeder, Tina M. M., Hsu, Chen-Jen, Becker, Alicia L., Zhang, Qirui, Mohr, Juliane, Frey, Stephanie, Scholl, Sebastian, Bullinger, Lars, Lane, Steven W. and Heidel, Florian H. (2022). Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans La, Dec 10-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2022-157247

Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

2022

Conference Publication

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Bruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne T., Cheng, Guidan, Kahl, Vivian F.S., Sobinoff, Alexander, Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda, Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2022). Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-168166

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

2022

Conference Publication

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Gill, Harinder, Palandri, Francesca, Ross, David M., Cochrane, Tara, Tate, Courtney, Lane, Steven W., Larsen, Stephen R., Gerds, Aaron T., Halpern, Anna B., Shortt, Jake, Rossetti, James M., Pettit, Kristen M., Liang, James, Mead, Adam J., Marchetti, Monia, Vannucchi, Alessandro M., Wilson, Andrew J., Goethert, Joachim R., Hanna, Merit, Passamonti, Francesco, Stevenson, William S., Harrison, Claire, Talpaz, Moshe, Vianelli, Nicola and Rienhoff, Hugh Young (2022). A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET). 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans La, Dec 10-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2022-159047

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

2022

Conference Publication

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Yeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S.M., Shortt, Jake, Burbury, Kate, Viiala, Nicholas, Cunningham, Ilona, Ross, David M., Harrup, Rosemary, Wright, Matthew, Forsyth, Cecily, D'Souza, Alwyn Bernard, Filshie, Robin J., Browett, Peter J., Lane, Steven W., Grove, Carolyn, Grigg, Andrew and Hughes, Timothy (2022). Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-157244

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

2021

Conference Publication

A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT<sub>3</sub>-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study)

Kipp, David, Loo, Sun, Perkins, Andrew Charles, Lane, Steven W., Blyth, Emily, Ejeti, Anoop Kumar, Bajel, Ashish, Reynolds, John and Wei, Andrew H. (2021). A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-154247

A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT<sub>3</sub>-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study)

2021

Conference Publication

Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia

Ling, Victoria Y., Jacquelin, Sebastien, Straube, Jasmin, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne T., Bruedigam, Claudia, Cooper, Emily, Godfrey, William, Tey, Siok-Keen, Bullinger, Lars, Herold, Marco J., Baell, Jonathan, Bywater, Megan and Lane, Steven W. (2021). Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-148379

Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia

2021

Conference Publication

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Palandri, Francesca, Vianelli, Nicola, Ross, David M., Cochrane, Tara, Lane, Steven W., Larsen, Stephen R., Gerds, Aaron T., Halpern, Anna B., Shortt, Jake, Rossetti, James M., Pettit, Kristen M., Jones, Amber, Peppe, Jennifer, Natsoulis, Georges, Navarro, Willis, Hong, Wan-Jen, Stevenson, William S., Harrison, Claire N., Talpaz, Moshe and Rienhoff, Hugh Young (2021). A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-148210

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

2021

Conference Publication

PREDICTORS OF AND TIME FRAME FOR READMISSION FOLLOWING HOSPITALISATION WITH COMMUNITY ACQUIRED PNEUMONIA

Chakrabarti, B., Lane, S., Jenks, T., Higgins, J., Kanwar, E., Allen, M. and Wootton, D. G. (2021). PREDICTORS OF AND TIME FRAME FOR READMISSION FOLLOWING HOSPITALISATION WITH COMMUNITY ACQUIRED PNEUMONIA. Winter Meeting of the British-Thoracic-Society (BTS), Electr Network, Feb 17-19, 2021. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/thorax-2020-BTSabstracts.106

PREDICTORS OF AND TIME FRAME FOR READMISSION FOLLOWING HOSPITALISATION WITH COMMUNITY ACQUIRED PNEUMONIA

2018

Conference Publication

Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon

Varelias, Antiopi, Bunting, Mark, Ormerod, Kate, Koyama, Motoko, Olver, Stuart, Straube, Jasmin, Kuns, Rachel, Robb, Renee, Henden, Andrea, Cooper, Leanne, Lachner, Nancy, Gartlan, Kate, Lantz, Olivier J., Kjer-Nielsen, Lars, Mak, Jeffrey, Fairlie, David, Clouston, Andrew, McCluskey, James, Rossjohn, Jamie, Lane, Steven, Hugenholtz, Phil and Hill, Geoff (2018). Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon. Immunology 2018™ Meeting, Austin, TX United States, 4-8 May 2018. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.200.supp.55.15

Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon

2016

Conference Publication

IL-28 Is a critical cytoprotectant in transplantation

Henden, A., Robb, R., Clouston, A., Kuns, R., Lane, S., Gartlan, K. and Hill, G. (2016). IL-28 Is a critical cytoprotectant in transplantation. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Weinheim, Germany: Wiley-VCH.

IL-28 Is a critical cytoprotectant in transplantation

2015

Conference Publication

SSB1 AND SSB2 SINGLE-STRANDED DNA BINDING PROTEINS ARE ESSENTIAL FOR HSC FUNCTION

Vu, Therese, Shi, Wei, Lane, Steven and Khanna, Kum Kum (2015). SSB1 AND SSB2 SINGLE-STRANDED DNA BINDING PROTEINS ARE ESSENTIAL FOR HSC FUNCTION. 44th Annual Scientific Meeting of the International-Society-for-Experimental-Hematology (ISEH), Kyoto Japan, Sep 17-19, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.exphem.2015.06.274

SSB1 AND SSB2 SINGLE-STRANDED DNA BINDING PROTEINS ARE ESSENTIAL FOR HSC FUNCTION

2015

Conference Publication

The adaptor protein ASC controls transplantation outcomes independently of the inflammasome

Cheong, Melody, Gartlan, Kate, Tey, Siok-Keen, Kuns, Rachel, Lor, Mary, Lineburg, Katie, Tea, Bianca, Shi, Wei, Raju, Jyothy, Zhang, Ping, Varelias, Antiopi, Leveque-El Mouttie, Lucie, Olver, Stuart, Bunting, Mark, Lane, Steven, Boyle, Glen, Ting, Jenny, Schroder, Kate, Engwerda, Christian, Khanna, Kum Kum, Smyth, Mark, MacDonald, Kelli, Koyama, Motoko and Hill, Geoffrey (2015). The adaptor protein ASC controls transplantation outcomes independently of the inflammasome. Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY), New Orleans La, May 08-12, 2015. BETHESDA: AMER ASSOC IMMUNOLOGISTS.

The adaptor protein ASC controls transplantation outcomes independently of the inflammasome

2014

Conference Publication

Investigation of mice deficient in matriptase-2, Hfe and transferrin receptor 2 reveals a novel non-hepatic role for Tfr2 in erythropoiesis

Wallace, D. F., Secondes, E. S., Rishi, G., Ostini, L., Mcdonald, C. J., Lane, S. W., Hooper, J. D., Lopez-Otin, C. and Subramaniam, V. N. (2014). Investigation of mice deficient in matriptase-2, Hfe and transferrin receptor 2 reveals a novel non-hepatic role for Tfr2 in erythropoiesis. Australian Gastroenterology Week 2014, Broadbeach, Australia, 22-24 October 2014. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736_6

Investigation of mice deficient in matriptase-2, Hfe and transferrin receptor 2 reveals a novel non-hepatic role for Tfr2 in erythropoiesis

2012

Conference Publication

Structure and RNA Recognition in Recombinant STNV Capsids

Phillips, Simon Edward Victor, Lane, Stephen W., Dennis, Caitriona A., Lane, Claire L., Trinh, Chi H., Rizkallah, Pierre J., Bunka, David H., Dykeman, Eric C., Ford, Robert, Barker, Amy, Twarock, Reidun and Stockley, Peter G. (2012). Structure and RNA Recognition in Recombinant STNV Capsids. 56th Annual Meeting of the Biophysical-Society, San Diego Ca, Feb 25-29, 2012. CAMBRIDGE: CELL PRESS.

Structure and RNA Recognition in Recombinant STNV Capsids

2011

Conference Publication

Mtor complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis

Kalaitzidis, Demetrios, Sykes, Stephen M., Punt, Natalie, Tang, Yuefeng, Lane, Steven W., Clish, Clary, Gilliland, D. Gary, Scadden, David T., Guertin, David and Armstrong, Scott A. (2011). Mtor complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States, 10-13 Dec 2011. Washington, DC, United States: American Society of Hematology.

Mtor complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis

2011

Conference Publication

Pak A proteins are essential for hematopoietic stem/progenitor cell (HSC/P) engraftment through regulation of signaling pathways controlling HSC/P proliferation, survival, migration, and the actin cytoskeleton

Dorrance, Adrienne M., Kosoff', Rachelle, McGuinness, Meaghan, Harris, Chad, De Vita, Serena, Mathieu, Ronald, Lane, Steven W., Milsom, Michael D., Chernoff, Jonathan and Williams, David A. (2011). Pak A proteins are essential for hematopoietic stem/progenitor cell (HSC/P) engraftment through regulation of signaling pathways controlling HSC/P proliferation, survival, migration, and the actin cytoskeleton. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States, 10-13 Dec 2011. Washington, DC, United States: American Society of Hematology.

Pak A proteins are essential for hematopoietic stem/progenitor cell (HSC/P) engraftment through regulation of signaling pathways controlling HSC/P proliferation, survival, migration, and the actin cytoskeleton

2011

Conference Publication

Evaluating clonal dominance in a murine knock-in model of Jak2V617F MPN

Mullally, Ann, Poveromo, Luke, Brumme, Kristina, Al-Shahrour, Fatima, Lane, Steven W., Shih, Alan H., Aifantis, Iannis, Levine, Ross L. and Ebert, Benjamin L. (2011). Evaluating clonal dominance in a murine knock-in model of Jak2V617F MPN. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States, 10-13 Dec 2011. Washington, DC, United States: American Society of Hematology.

Evaluating clonal dominance in a murine knock-in model of Jak2V617F MPN

2011

Conference Publication

Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias

Sykes, S. M., Lane, S. W., Bullinger, L., Demetrios, K., Yusuf, R., Saez, B., Ferraro, F., Mercier, F., Singh, H., Brumme, K. M., Acharya, S., Scholl, C., Tothova, Z., Attar, E., Froehling, S., DePinho, R. A., Gilliland, D. G., Armstrong, S. A. and Sca, D. T. (2011). Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias. ISEH 40th Annual Scientific Meeting, -, 25 - 28 August 2011. Philadelphia, PA, United States: Elsevier.

Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias

2011

Conference Publication

Myeloid leukemogenesis driven by aberrant CDX2 expression involves transcriptional repression of KLF4 and deregulated PPAR gamma signaling

Faber, Katrin, Bullinger, Lars, Garding, Angela, Mertens, Daniel, Martin, Daniela, Walcher, Daniel, Doehner, Konstanze, Doehner, Hartmut, Sykes, Stephen M., Claus, Rainer, Plass, Christoph, Lane, Steven W., Scholl, Claudia and Froehling, Stefan (2011). Myeloid leukemogenesis driven by aberrant CDX2 expression involves transcriptional repression of KLF4 and deregulated PPAR gamma signaling. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States, 10-13 Dec 2011. Washington, DC, United States: American Society of Hematology.

Myeloid leukemogenesis driven by aberrant CDX2 expression involves transcriptional repression of KLF4 and deregulated PPAR gamma signaling

2010

Conference Publication

Characterizing the disease-initiating cell population in a murine model of Jak2V617F+ myeloproliferative neoplasm

Mullally, Ann, Lane, Steven W., Poveromo, Luke, Al-Shahrour, Fatima, Kutok, Jeffery and Ebert, Benjamin L. (2010). Characterizing the disease-initiating cell population in a murine model of Jak2V617F+ myeloproliferative neoplasm. 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, United States, 4-7 Dec 2010. Washington, DC, United States: American Society of Hematology.

Characterizing the disease-initiating cell population in a murine model of Jak2V617F+ myeloproliferative neoplasm